Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.54 |
| ▸ | ACACA | Q13085 | 1/20 | 0.54 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.31 |
| ▸ | ACLY | P53396 | 1/20 | 0.31 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1106793 | 0.99 | ACACB (0.51) | ACACBACACAFFAR4FFAR1 | |
| SCHEMBL1106804 | 0.93 | ACACB (0.49) | ACACBACACACYP4F2CYP4A11TBXAS1 | |
| SCHEMBL186569 | 0.90 | ACACB (0.69) | ACACBACACAFFAR4FFAR1CYP4F2 | |
| SCHEMBL798275 | 0.90 | ACLY (0.37) | ACACBACACAFFAR1CYP4F2CYP4A11 | |
| SCHEMBL186855 | 0.89 | ACACB (0.66) | ACACBACACAFFAR4FFAR1ACLY | |
| SCHEMBL13818712 | 0.83 | ACACB (0.67) | ACACBACACAFFAR4FFAR1CYP4F2 | |
| SCHEMBL5902987 | 0.83 | ACACB (0.46) | ACACBACACAFFAR4FFAR1CYP4F2 | |
| SCHEMBL186576 | 0.83 | FFAR4 (0.40) | ACACBACACAFFAR4FFAR1CYP4F2 | |
| SCHEMBL1106767 | 0.83 | ACACB (0.62) | ACACBACACAFFAR4FFAR1CYP4F2 | |
| SCHEMBL2737166 | 0.82 | ACACB (0.45) | ACACBACACAFFAR4FFAR1CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8623915-B2 | Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20130040916-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| US-8309604-B2 | Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120172337-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-8153690-B2 | Cycloalkyl-hydroxyl compounds and compositions for cholesterol management | ESPERION THERAPEUTICS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20120035141-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT | ESPERION THERAPEUTICS, INC. (US) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035141-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT | PNLIP, NR1H3, NR1H2 | ACACB 269/4885ACACA 207/4885FFAR4 241/4885 |
| US-20120172337-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PNLIP, NR1H3, NR1H2 | ACACB 204/4885ACACA 158/4885FFAR4 295/4885 |
| US-20130040916-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PNLIP, NR1H3, NR1H2 | ACACB 204/4885ACACA 158/4885FFAR4 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.